Narjust Florez, Co-Director of Young Lung Cancer Program at Dana-Farber Cancer Institute, shared on X:
“Proud to share our latest international multicenter study, which I had the privilege of co-authoring with an incredible group of collaborators.
Together, we explored whether patients with advanced NSCLC and pre-existing pericardial effusions can safely receive immunotherapy. Our findings provide reassuring real-world evidence that may help guide treatment decisions.
Swipe through for the key takeaways.”
Title: Effectiveness and Safety of Immunotherapy in Advanced NSCLC with Pericardial Effusions: A Global Retrospective Multicenter Study
Authors: Talal El Zarif, Sarah Abou Alaiwi, Amin H Nassar, Eleonora Gariazzo, Valentina Santo, Edoardo Garbo, Mihaela Aldea, Francesco Paoloni, Sagal Pannu, Karl Semaan, Omar Chehab, Malak Hoballah, Vishal Navani, Yizhuo Gao, Daniel Meyers, Igor Stukalin, Arjun Mittra, Mingjia Li, Nicholas Jones, Shirly Grynberg, Ronnie Shapira, Alexi Vasbinder, Salim S Hayek, Elias Bou Farhat, Marc Eid, Eddy Saad, Dory Freeman, Kaushal Parikh, Aakash Desai, Caleb Smith, Edward El-Am, Frank Aboubakar Nana, Simone Foderaro, Javier Baena, Mercedes Herrera, Alessio Cortellini, David J Pinato, James Korolewicz, Chul Kim, Paul Sackstein, Ryan A Denu, Walid Macaron, Noha Abdel-Wahab, Tomas G Neilan, João A C Lima, Narjust Florez, Pasi Janne, Biagio Ricciuti, Federica Pecci, Toni K Choueiri, Jennifer M Kwan, Abdul Rafeh Naqash
Other articles featuring Narjust Florez on OncoDaily.